References
- Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 103(1–2), 91–95 (2004).
- Kayali G, Setterquist SF, Capuano AW, Myers KP, Gill JS, Gray GC. Testing human sera for antibodies against avian influenza viruses: horse RBC hemagglutination inhibition vs. microneutralization assays. J. Clin. Virol. 43(1), 73–78 (2008).
- Stephenson I, Heath A, Major D et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerging Infect. Dis. 15(8), 1252–1259 (2009).
- Russell SM, McCahon D, Beare AS. A single radial haemolysis technique for the measurement of influenza antibody. J. Gen. Virol. 27(1), 1–10 (1975).
- Zambon MC. Laboratory diagnosis of influenza. In: Influenza. Nicholson KG, Webster RG, Hay AJ (Eds.). Blackwell Publishing, Oxford, UK, 123–156 (1997).
- Eichelberger M, Golding H, Hess M et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10–11, 2007. Vaccine 26(34), 4299–4303 (2008).
- Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 25(20), 4056–4063 (2007).
- Wood JM, Montomoli E, Newman RW, Daas A, Buchheit KH, Terao E. Collaborative study on influenza vaccine clinical trial serology – part 2: reproducibility study. Pharmeur. Bio Sci. Notes 2011(1), 36–54 (2011).
- Wood JM, Major D, Heath A et al. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine 30(2), 210–217 (2012).
- Wagner R, Göpfert C, Hammann J et al. Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines – an effective EU regulatory approach. Vaccine 30(27), 4113–4122 (2012).
- de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. In: Laboratory Correlates of Immunity to Influenza – a Reassessment. Brown F, Haaheim LR, Schild GC (Eds). Karger, Basel, Switzerland, 63–73 (2003).
- Wood JM, Newman RW, Ploss K. The use of correlates of immunity in European Union licensing of influenza vaccines. In: Laboratory Correlates of Immunity to Influenza – a Reassessment. Brown F, Haaheim LR, Schild GC (Eds). Karger, Basel, Switzerland, 9–16 (2003).
- Epstein SL, Price GE. Cross-protective immunity to influenza A viruses. Expert Rev. Vaccines 9(11), 1325–1341 (2010).
- Lambert LC, Fauci AS. Influenza vaccines for the future. N. Engl. J. Med. 363(21), 2036–2044 (2010).
- Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 26(Suppl. 4), D41–D44 (2008).
Websites
- The European Agency for the Evaluation of Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf
- European Medicines Agency. Concept paper on the revision of guidelines for influenza vaccines. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/10/WC500115612.pdf
- WHO Expert Committee on Biological Standardisation. Report of a WHO collaborative study to assess the suitability of a candidate International Standard for antibody to pandemic H1N1 influenza virus, 2010: IS09/94. http://whqlibdoc.who.int/hq/2010/WHO_BS_10.2137_eng.pdf